Priority Healthcare Corp.

Changes in oncology reimbursement will affect pharmaceutical manufacturers' relationships with providers and payers as well as their development and commercialization strategies. By Wendy Diller Until

As biotech products ripen, manufacturers ponder how best to get them to patients. Specialty pharmacy providers can help, but which is worth the money? By Wendy Diller These days, more and more biotech

The steady stream of new biologics—by some counts more than 300 biologics are in development or under FDA review--puts increasing pressure on both payers and manufacturers to re-evaluate long-standing